Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics
Teixeira, Antônio Lúcio , Gregg, Allison, Gentry, Melanie T. , Rapp, Ellie, Oberlin, Lauren E. , Ajilore, Olusola , Teixeira, Antonio L , Gujral, Swathi , Oberlin, Lauren, Ajilore, Olusola , Weisenbach, Sara, Gentry, Melanie T , Rapp, Ellie, Weisenbach, Sara L. , Patrick, Regan

Focus | April 15, 2025 | Volume: 23 | Issue: 2 | Pages: 183-194

10.1176/appi.focus.20240046 | PMID 40235602 Get It

Combined TaTME with SP Robot for Low Anterior Resection in Rectal Cancer: rSPa TaTME
Keshk, Nouran O., Perez-Pachon, Mauricio E., Gomaa, Ibrahim A. , Aboelmaaty, Sara , Rumer, Kristen K. , Shawki, Sherief , Gomaa, Ibrahim , Keshk, Nouran O., Larson, David W.

Cancers | April 15, 2025 | Volume: 17 | Issue: 8 | Pages: 1328

10.3390/cancers17081328 | PMID 40282504 Get It

Background: Total mesorectal excision (TME) remains the gold standard for the resection of rectal cancer regardless of the modality: open, laparoscopic, or robotic. The transanal TME (TaTME) approach has been utilized to overcome the difficulties encountered with the dissection of tumors in the distal pelvis. Recently, a single-port robotic approach (rSPa) was introduced, where three arms and a camera emanate from a 2.5 cm diameter port. This report presents the first experience in the United States combining those two approaches (rSPa TaTME) in rectal cancer, evaluating its safety and oncologic outcomes. Methods: This is a retrospective review of our prospectively maintained rectal cancer database. Patient demographics, tumor characteristics, neoadjuvant treatment, and oncologic and surgical outcomes were recorded. Results: Between May 2022 and August 2024, ten patients (six females, four males) with a median age at surgery of 53 years (range: 38–85) and a mean BMI of 26 (±5) kg/m2 were included for analysis. The median distance of tumors from the anorectal junction was 3.2 cm (range: 2–5.3 cm). All patients had negative margins, with eight complete TME specimens, one near complete, and one incomplete. The mean number of lymph nodes harvested was 24 (±11). The average operative time was 351 (243–411) min. The average length of stay was four days. The ileostomy was reversed in nine out of ten patients. Six patients experienced complications within 30 days of surgery. There were no local or distal recurrences, with a mean follow-up of 20 months (range: 4–30). Conclusions: rSPa TaTME is a unique and innovative method of combining two minimally advanced approaches for the resection of distal rectal cancers, with acceptable surgical and oncologic outcomes.
Autologous Transplant or CAR‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments
Furqan, Fateeha , Ahn, Kwang Woo , Kaur, Manmeet , Patel, Jinalben , Ansell, Stephen M. , Awan, Farrukh T. , Baird, John H. , Farooq, Umar , Fung, Henry C., Khurana, Arushi , Lekakis, Lazaros J. , Lutfi, Forat , McCarty, John M. , Mukherjee, Akash , Nath, Rajneesh , Winter, Allison , Sauter, Craig S. , Herrera, Alex F. , Smith, Melody , Ansell, Stephen M , Baird, John , Khurana, Arushi , Winter, Allison , Shadman, Mazyar , Herrera, Alex F , Awan, Farrukh T , Smith, Melody , Bezerra, Evandro D. , Farooq, Umar, Romancik, Jason T. , Schuster, Stephen J. , Smith, Melody , Turtle, Cameron J. , Shadman, Mazyar , Hamadani, Mehdi

American Journal of Hematology | April 15, 2025 | Volume: 100 | Issue: 7 | Pages: 1152-1162

10.1002/ajh.27687 | PMID 40231369 Get It

ABSTRACTAlthough recent studies have demonstrated the efficacy of chimeric antigen receptor T‐cell (CAR‐T) therapy in relapsed large B‐cell lymphoma (LBCL) with MYC rearrangement (R‐MYC), the data comparing CAR‐T to autologous hematopoietic cell transplant (auto‐HCT) in such patients who achieve a complete or partial response (CR/PR) after salvage therapies are limited. We compared the clinical outcomes of patients with R‐MYC LBCL (including double and triple hit lymphomas) who underwent CAR‐T or auto‐HCT after achieving a CR/PR with salvage therapies using the Center for International Blood & Marrow Transplant Research registry. Among the 252 patients (auto‐HCT = 98, CAR‐T = 154), relative to auto‐HCT, CAR‐T was associated with significantly lower overall survival (OS) (Hazard Ratio [HR] 2.09, 95% CI 1.38–3.15, p < 0.001) on multivariate analysis. There were no differences in progression‐free survival (PFS) (HR 1.21, 95% CI 0.81–1.8 p = 0.36), risk of relapse (HR 1.1, 95% CI 0.71–1.69 p = 0.68), nonrelapse mortality (NRM) (HR 1.74, 95% CI 0.64–4.7 p = 0.28) while the post‐relapse survival was longer in auto‐HCT relative to CAR‐T (HR 1.93, 95% CI 1.21–3.06 p = 0.01). On propensity score matched analysis accounting for differences in characteristics across the two cohorts, we detected no significant differences in OS (HR 1.72, 95% CI 0.92–3.21 p = 0.09), PFS (HR 1.04, 95% CI 0.64–1.68 p = 0.88), NRM (HR 1.22, 95% CI 0.35–4.2 p = 0.76), relapse (HR = 0.93, 95% CI 0.54–1.6 p = 0.8) and post‐relapse survival (HR 2.25, 95% CI 0.98–5.17, p = 0.06). These data, although retrospective, support consideration for auto‐HCT in patients with R‐MYC LBCL who achieve a CR/PR after salvage therapies, particularly in regions with no or limited access to CAR‐T.
Practice Standards for Acute Hospital Care at Home
Levine, David M. , DeCherrie, Linda V. , Siu, Albert L. , Schiller, Gabrielle , Timpe, Chrisanne , Murphy, Stephanie , Lung, C. P., Nottidge, Michael, Titchener, Karen , Paulson, Margaret, Paulson, Margaret R. , Leff, Bruce A.

Journal of the American Geriatrics Society | April 15, 2025 | Volume: 73 | Issue: 7 | Pages: 2037-2045

10.1111/jgs.19427 | PMID 40156507 Get It

ABSTRACT Background Hospital at home (HaH) provides hospital‐level care at home as a substitute for brick‐and‐mortar hospital care. Multiple HaH studies demonstrate HaH provides safe, high‐quality, cost‐effective care. However, practices have varied approaches to delivering care and no HaH‐specific national standards exist. We aimed to develop national practice standards for HaH and assess practice performance against the standards. Methods The HaH Users Group (HaHUG), the national convener of HaH practices, assembled the Practice Standards Council in 2019 to develop evidence‐based standards for HaH. We reviewed existing international standards and the requirements of the Centers for Medicare and Medicaid Services Acute Hospital Care at Home Waiver. We engaged in multiple iterative rounds to develop domains and standards within each domain and then held an open comment period. We distributed an online survey for all HaHUG practices to self‐assess whether they did not meet (score, −1), met (score, 0), or exceeded (score, +1) each standard. The American Hospital Association's Annual Survey was used to describe practices that did and did not complete the practice standards survey. Results Final practice standards included 31 standards in 7 domains: leadership; education and training; human resources management; quality and quality improvement; safe practice and environment; and clinical standards and protocols. The majority of HaH practices self‐rated that they met or exceeded standards: scores ranged from −5 to 31; mean score of 9.75 (SD, 12.60). Forty‐nine of 213 eligible HaH practices completed the survey (response rate, 23.0%). Most hospitals were large (65% > 299 beds), nonprofit (85%), teaching (90%) centers that cared for a large proportion of patients with Medicaid. Conclusion We present the first national practice standards for HaH. The vast majority of HaH practices met or exceeded these standards by their own assessment. There was a range of performance across standards, demonstrating strengths and opportunities for ongoing development and quality improvement.
Medicaid Reimbursement for Common Orthopaedic Foot and Ankle Procedures Is Highly Inconsistent Among States, Ranging from 37% to 324% of Medicare Reimbursement
Adám, H , Moore, M. Lane , Beckett, Nathan , Schuyver, Paul R. Van, Haglin, Jack M. , Brinkman, Joseph C. , Adam, Henderson , Beckett, Nathan C, Moore, M Lane , Schuyver, Paul Van , Patel, Karan A.

Foot & Ankle Orthopaedics | April 15, 2025 | Volume: 10 | Issue: 2 | Pages: No page available

10.1177/24730114251330302 | PMID 40297401 Get It

Background: Medicaid reimbursement to physicians is often perceived to be lower than Medicare, but little is known about orthopaedic foot and ankle reimbursement. This study sought to compare Medicare and Medicaid reimbursement for the 20 most common foot and ankle procedures. Methods: Medicare reimbursement rates for common foot and ankle codes were obtained from the online Centers for Medicare & Medicaid fee schedule, while Medicaid rates were found from individual state fee schedule websites. Medicaid rates were compared by state and pooled to obtain national differences. The Medicare Wage Index was used to adjust Medicaid rates by state wages to ensure a more accurate comparison. Variability between states was measured using state percentages of Medicare and coefficient of variation values. Results: Medicaid reimbursed physicians higher than Medicare in 31 states overall, with average reimbursement ranging from 37% to 324% of Medicare. Nationally, Medicaid reimbursed 8.8% higher than Medicare, but Medicare reimbursed 3.7% higher when adjusted for the Medicare Wage Index. The Current Procedural Terminology ( CPT ) codes with the highest ratio of Medicaid to Medicare reimbursement were CPT 28002 for incision and drainage of the foot (176.6%) and CPT 28820 for toe amputation (167.6%). Five codes had lower relative Medicaid reimbursement on average: CPT 27687 for repair procedures on the leg and ankle joint, CPT 28810 for amputation procedures on the foot and toes, CPT 28010 for toe tenotomy, CPT 28005 for incision procedures on the foot and toes, and CPT 28470 for closed treatment of a metatarsal fracture. The coefficient of variation values ranged from 0.34 to 0.84 in the Medicaid group and 0.40 to 0.78 in the adjusted group, indicating high variability between states and between procedures. Conclusion: Medicaid reimbursement is highly inconsistent between states, ranging from 37% to 324% of Medicare. Medicaid reimbursed more than Medicare overall, which is in contrast with most published findings that tend to show higher reimbursement for Medicare when compared to Medicaid. When adjusting for wage differences between states, Medicare reimbursed slightly higher than Medicaid. Level of Evidence: Level IV, economic analysis.
Anhedonia as a Core Symptom of Depression and a Construct for Biological Research
Al‐Soleiti, Majd , Voort, Jennifer L. Vande , Singh, Balwinder , Singh, Balwinder

Focus | April 15, 2025 | Volume: 23 | Issue: 2 | Pages: 163-172

10.1176/appi.focus.20240050 | PMID 40235618 Get It

The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts
Xue, Zhiyi , Mladek, Ann C. , Odukoya, Lateef A , Liu, Lily, Carlson, Brett L. , Ott, Lauren L. , Hu, Zeng, Decker, Paul A. , Kosel, Matthew , Breen, William G. , Eckel‐Passow, Jeanette E. , Elmquist, William F. , Zhong, Wei , Sarkaria, Jann N. , Dragojevic, Sonja , Decker, Paul A. , Sarkaria, Jann N , Mladek, Ann C , Odukoya, Lateef A , Rathi, Sneha , Jain, Sonia , Vaubel, Rachael A. , Garcia, D. , Bakken, Katrina K. , Burgenske, Danielle M. , Gupta, Shiv K. , Zhong, Wei

Neuro-Oncology | April 15, 2025 | Volume: 27 | Issue: 9 | Pages: 2313-2325

10.1093/neuonc/noaf102 | PMID 40230030 Get It

Abstract Background The ataxia-telangiectasia mutated (ATM) protein coordinates the cellular response to therapeutic radiation, and ATM inhibitors can potentially enhance the efficacy of radiation in otherwise radiation-resistant tumors. Methods The small molecule ATM kinase inhibitor WSD0628 was specifically designed for enhanced distribution across the blood-brain barrier to more effectively treat glioblastoma (GBM) and brain metastases in combination with radiation therapy (RT). GBM and brain metastasis patient-derived xenograft models were used to understand target inhibition, radiosensitization, inhibition of the DNA damage response, and in vivo efficacy. Results Initial in vitro characterization of WSD0628 demonstrates a high level of selectivity across kinase families, limited aldehyde oxidase liability, and low risk of hERG interactions. Consistent with a central role for ATM in radiation response, WSD0628 blocked radiation-induced signaling and enhanced radiosensitivity in U251 glioma cells and brain tumor PDXs GBM120 and M12. In comparison to control or RT alone in orthotopic PDXs, the combination of WSD0628 with RT markedly prolonged median survival—GBM12 (19, 55, and 408 days, respectively); GBM43 (26, 44, and 143 days, respectively); GBM120 (51, 89, and 231 days, respectively); M12 (17, 39, and 190 days, respectively). Pharmacokinetic and pharmacodynamic testing after treatment in orthotopic GBM43 tumors showed inhibitory levels of WSD0628 and a reduction of γH2AX foci in the combination-treated tumors. Conclusions Collectively, these results suggest a promising role for WSD0628 in combination with RT in brain tumors and provide the rationale for an ongoing Phase 0/1A clinical trial testing this combination in recurrent GBM.
Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol
Reitinger, Jeremy C. , Reed, David M. , Peres, Cameron , Fan, Shan , Gulati, Vikas , Kazemi, Arash , Sit, Arthur J. , Moroi, Sayoko E. , Toris, Carol B. , Moroi, Sayoko E , Sit, Arthur J

Journal of Ocular Pharmacology and Therapeutics | April 14, 2025 | Volume: 41 | Issue: 5 | Pages: 251-258

10.1089/jop.2024.0112 | PMID 40229142 Get It

Purpose: To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. Methods: In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. Results: More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff ( p < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs ( p < 0.01). Among timolol nonresponders ( n = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders ( n = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. Conclusions: Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.